Results 161 to 170 of about 5,401 (225)
Diverse effects of calcineurin in vascular smooth muscle cells: physiological activators and the controversial actions of clinical inhibitors. [PDF]
Front PharmacolNolze A, Grossmann C.
europepmc +1 more source
Pimecrolimus in dermatology: atopic dermatitis and beyond [PDF]
International Journal of Clinical Practice, 2005 Pimecrolimus is a calcineurin inhibitor developed for the topical therapy of inflammatory skin diseases, particularly atopic dermatitis (AD). Pimecrolimus selectively targets T cells and mast cells.
Giampiero Girolomoni +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of the European Academy of Dermatology and Venereology, 2003
ABSTRACTPimecrolimus (SDZ ASM 981), an ascomycin derivative, is one of the new classes of immunomodulating macrolactams and was specifically developed for the treatment of inflammatory skin diseases. The interest in pimecrolimus has been substantial because of its significant anti‐inflammatory activity and immunomodulatory capabilities and its low ...
exaly +3 more sources
ABSTRACTPimecrolimus (SDZ ASM 981), an ascomycin derivative, is one of the new classes of immunomodulating macrolactams and was specifically developed for the treatment of inflammatory skin diseases. The interest in pimecrolimus has been substantial because of its significant anti‐inflammatory activity and immunomodulatory capabilities and its low ...
exaly +3 more sources
The Lancet Child & Adolescent Health, 2022
BACKGROUND Atopic dermatitis is a prevalent condition in children and can be effectively managed with medications such as topical calcineurin inhibitors (pimecrolimus or tacrolimus).
N. Devasenapathy +12 more
semanticscholar +1 more source
BACKGROUND Atopic dermatitis is a prevalent condition in children and can be effectively managed with medications such as topical calcineurin inhibitors (pimecrolimus or tacrolimus).
N. Devasenapathy +12 more
semanticscholar +1 more source
Reactions Weekly, 2004
Pimecrolimus (Elidel) is a topically active, nonsteroid, calcineurin inhibitor that has shown efficacy in controlling symptoms of atopic dermatitis in adult and pediatric patients. Topical pimecrolimus 1% cream is approved in the US for the short-term and intermittent long-term treatment of mild-to-moderate atopic dermatitis in non-immunocompromised ...
Keri, Wellington, Stuart, Noble
+5 more sources
Pimecrolimus (Elidel) is a topically active, nonsteroid, calcineurin inhibitor that has shown efficacy in controlling symptoms of atopic dermatitis in adult and pediatric patients. Topical pimecrolimus 1% cream is approved in the US for the short-term and intermittent long-term treatment of mild-to-moderate atopic dermatitis in non-immunocompromised ...
Keri, Wellington, Stuart, Noble
+5 more sources
The Lancet Haematology, 2022
BACKGROUND The calcineurin pathway is often activated in mycosis fungoides. We aimed to assess the activity and safety of topical pimecrolimus, a calcineurin inhibitor, in patients with early mycosis fungoides.
P. Ortiz-Romero +19 more
semanticscholar +1 more source
BACKGROUND The calcineurin pathway is often activated in mycosis fungoides. We aimed to assess the activity and safety of topical pimecrolimus, a calcineurin inhibitor, in patients with early mycosis fungoides.
P. Ortiz-Romero +19 more
semanticscholar +1 more source